Cutting edge issues in autoimmune hepatitis

Journal of Autoimmunity

Volumn 75, Issue , 2016, Pages 6-19

  Liberal, Rodrigo ^a   Krawitt, Edward L ^b,c   Vierling, John M ^d   Manns, Michael P ^e   Mieli Vergani, Giorgina ^a   Vergani, Diego ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Autoimmune hepatitis; Immunosuppression; International Autoimmune Hepatitis Group; Pathogenesis

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; AZATHIOPRINE; BIOLOGICAL PRODUCT; BUDESONIDE; CALCINEURIN INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLATE MOFETIL; PREDNISOLONE; PREDNISONE; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT;

ACUTE LIVER FAILURE; AUTOIMMUNE HEPATITIS; CLINICAL FEATURE; END STAGE LIVER DISEASE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; HYPERGAMMAGLOBULINEMIA; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LIVER HISTOLOGY; LIVER TRANSPLANTATION; NONHUMAN; PATHOGENESIS; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SALVAGE THERAPY; SCORING SYSTEM; T LYMPHOCYTE; TOXIC HEPATITIS; COMBINATION DRUG THERAPY; DRUG EFFECTS; GENETIC PREDISPOSITION; GENETICS; HEPATITIS, AUTOIMMUNE; IMMUNOLOGY; LIVER; SURGERY;

AZATHIOPRINE; DRUG THERAPY, COMBINATION; GENETIC PREDISPOSITION TO DISEASE; HEPATITIS, AUTOIMMUNE; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER; LIVER TRANSPLANTATION; PREDNISOLONE;

EID: 84990977186     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2016.07.005     Document Type: Review

References (144)

1. [1] Leber, Waldenström J., Blutprotein und nahrungseiweiss. Dtsch. Gesellshaff Z Verdan Stoffwechselkr 15 (1950), 113–119.
2. [2] Mackay, I.R., Historical reflections on autoimmune hepatitis. World J. Gastroenterol. 14 (2008), 3292–3300.
3. [3] Mackay, I.R., Cowling, D.C., Taft, L.I., Lupoid hepatitis. Lancet 271 (1956), 1323–1326.
4. [4] Cook, G.C., Mulligan, R., Sherlock, S., Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q. J. Med. 40 (1971), 159–185.
5. [5] Soloway, R.D., Summerskill, W.H., Baggenstoss, A.H., Geall, M.G., Gitnick, G.L., Elveback, I.R., Schoenfield, L.J., Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 63 (1972), 820–833.
6. [6] Murray-Lyon, I.M., Stern, R.B., Williams, R., Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1 (1973), 735–737.
7. [7] Liberal, R., Selmi, C., Gershwin, M.E., Diego and giorgina vergani: the two hearts of translational autoimmunity. J. Autoimmun. 66 (2016), 1–6.
8. [8] Mackay, I.R., Weiden, S., Hasker, J., Autoimmune hepatitis. Ann. N. Y. Acad. Sci. 124 (1965), 767–780.
9. [9] Johnson, P.J., McFarlane, I.G., Meeting report: international autoimmune hepatitis group. Hepatology 18 (1993), 998–1005.
10. [10] Alvarez, F., Berg, P.A., Bianchi, F.B., Bianchi, L., Burroughs, A.K., Cancado, E.L., Chapman, R.W., et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J. Hepatol. 31 (1999), 929–938.
11. [11] Hennes, E.M., Zeniya, M., Czaja, A.J., Pares, A., Dalekos, G.N., Krawitt, E.L., Bittencourt, P.L., et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 48 (2008), 169–176.
12. [12] Liberal, R., Grant, C.R., Mieli-Vergani, G., Vergani, D., Autoimmune hepatitis: a comprehensive review. J. Autoimmun. 41 (2013), 126–139.
13. [13] Manns, M.P., Lohse, A.W., Vergani, D., Autoimmune hepatitis–update 2015. J. Hepatol. 62 (2015), S100–S111.
14. [14] Liberal, R., Longhi, M.S., Mieli-Vergani, G., Vergani, D., Pathogenesis of autoimmune hepatitis. Best. Pract. Res. Clin. Gastroenterol. 25 (2011), 653–664.
15. [15] Czaja, A.J., Manns, M.P., McFarlane, I.G., Hoofnagle, J.H., Autoimmune hepatitis: the investigational and clinical challenges. Hepatology 31 (2000), 1194–1200.
16. [16] Manns, M.P., Czaja, A.J., Gorham, J.D., Krawitt, E.L., Mieli-Vergani, G., Vergani, D., Vierling, J.M., et al. Diagnosis and management of autoimmune hepatitis. Hepatology 51 (2010), 2193–2213.
17. [17] Primo, J., Merino, C., Fernandez, J., Moles, J.R., Llorca, P., Hinojosa, J., Incidence and prevalence of autoimmune hepatitis in the area of the hospital de Sagunto (Spain). Gastroenterol. Hepatol. 27 (2004), 239–243.
18. [18] Ngu, J.H., Bechly, K., Chapman, B.A., Burt, M.J., Barclay, M.L., Gearry, R.B., Stedman, C.A., Population-based epidemiology study of autoimmune hepatitis: a disease of older women?. J. Gastroenterol. Hepatol. 25 (2010), 1681–1686.
19. [19] Hurlburt, K.J., McMahon, B.J., Deubner, H., Hsu-Trawinski, B., Williams, J.L., Kowdley, K.V., Prevalence of autoimmune liver disease in Alaska natives. Am. J. Gastroenterol. 97 (2002), 2402–2407.
20. [20] Boberg, K.M., Aadland, E., Jahnsen, J., Raknerud, N., Stiris, M., Bell, H., Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand. J. Gastroenterol. 33 (1998), 99–103.
21. [21] Whalley, S., Puvanachandra, P., Desai, A., Kennedy, H., Hepatology outpatient service provision in secondary care: a study of liver disease incidence and resource costs. Clin. Med. 7 (2007), 119–124.
22. [22] Gronbaek, L., Vilstrup, H., Jepsen, P., Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. J. Hepatol. 60 (2014), 612–617.
23. [23] Jimenez-Rivera, C., Ling, S.C., Ahmed, N., Yap, J., Aglipay, M., Barrowman, N., Graitson, S., et al. Incidence and characteristics of autoimmune hepatitis. Pediatrics 136 (2015), e1237–1248.
24. [24] Yoshizawa, K., Joshita, S., Matsumoto, A., Umemura, T., Tanaka, E., Morita, S., Maejima, T., et al. Incidence and prevalence of autoimmune hepatitis in the Ueda area, Japan. Hepatol. Res., 2015 Dec 15, 10.1111/hepr.12639 [Epub ahead of print].
25. [25] Karlsen, T.H., Lammert, F., Thompson, R.J., Genetics of liver disease: from pathophysiology to clinical practice. J. Hepatol. 62 (2015), S6–S14.
26. [26] Strettell, M.D., Donaldson, P.T., Thomson, L.J., Santrach, P.J., Moore, S.B., Czaja, A.J., Williams, R., Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology 112 (1997), 2028–2035.
27. [27] Czaja, A.J., Donaldson, P.T., Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol. Rev. 174 (2000), 250–259.
28. [28] Duarte-Rey, C., Pardo, A.L., Rodriguez-Velosa, Y., Mantilla, R.D., Anaya, J.M., Rojas-Villarraga, A., HLA class II association with autoimmune hepatitis in Latin America: a meta-analysis. Autoimmun. Rev. 8 (2009), 325–331.
29. [29] de Boer, Y.S., van Gerven, N.M., Zwiers, A., Verwer, B.J., van Hoek, B., van Erpecum, K.J., Beuers, U., et al. Genome-wide association study identifies variants associated with autoimmune hepatitis type-1. Gastroenterology 147 (2014), 443–452.
30. [30] Kirstein, M.M., Metzler, F., Geiger, E., Heinrich, E., Hallensleben, M., Manns, M.P., Vogel, A., Prediction of short- and long-term outcome in patients with autoimmune hepatitis. Hepatology 62 (2015), 1524–1535.
31. [31] van Gerven, N.M., de Boer, Y.S., Zwiers, A., Verwer, B.J., Drenth, J.P., van Hoek, B., van Erpecum, K.J., et al. HLA-DRB1*03:01 and HLA-DRB1*04:01 modify the presentation and outcome in autoimmune hepatitis type-1. Genes Immun. 16 (2015), 247–252.
32. [32] Vergani, D., Longhi, M.S., Bogdanos, D.P., Ma, Y., Mieli-Vergani, G., Autoimmune hepatitis. Semin. Immunopathol. 31 (2009), 421–435.
33. [33] Underhill, J.A., Ma, Y., Bogdanos, D.P., Cheeseman, P., Mieli-Vergani, G., Vergani, D., Different immunogenetic background in autoimmune hepatitis type 1, type 2 and autoimmune sclerosing cholangitis. J. Hepatol., 36, 2002 156–156.
34. [34] Bittencourt, P.L., Goldberg, A.C., Cancado, E.L., Porta, G., Carrilho, F.J., Farias, A.Q., Palacios, S.A., et al. Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2. Am. J. Gastroenterol. 94 (1999), 1906–1913.
35. [35] Djilali-Saiah, I., Fakhfakh, A., Louafi, H., Caillat-Zucman, S., Debray, D., Alvarez, F., HLA class II influences humoral autoimmunity in patients with type 2 autoimmune hepatitis. J. Hepatol. 45 (2006), 844–850.
36. [36] Oliveira, L.C., Porta, G., Marin, M.L., Bittencourt, P.L., Kalil, J., Goldberg, A.C., Autoimmune hepatitis, HLA and extended haplotypes. Autoimmun. Rev. 10 (2011), 189–193.
37. [37] Webb, G.J., Siminovitch, K.A., Hirschfield, G.M., The immunogenetics of primary biliary cirrhosis: a comprehensive review. J. Autoimmun. 64 (2015), 42–52.
38. [38] Webb, G.J., Hirschfield, G.M., Using GWAS to identify genetic predisposition in hepatic autoimmunity. J. Autoimmun. 66 (2015), 25–39.
39. [39] Liberal, R., Mieli-Vergani, G., Vergani, D., Contemporary issues and future directions in autoimmune hepatitis. Expert Rev. Gastroenterol. Hepatol., 2016, 1–12 [Epub ahead of print].
40. [40] Kerkar, N., Choudhuri, K., Ma, Y., Mahmoud, A., Bogdanos, D.P., Muratori, L., Bianchi, F., et al. Cytochrome P4502D6(193-212): a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease. J. Immunol. 170 (2003), 1481–1489.
41. [41] Manns, M.P., Griffin, K.J., Sullivan, K.F., Johnson, E.F., LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J. Clin. Invest 88 (1991), 1370–1378.
42. [42] Bogdanos, D.P., Choudhuri, K., Vergani, D., Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences. Liver 21 (2001), 225–232.
43. [43] Mackie, F.D., Peakman, M., Yun, M., Sallie, R., Smith, H., Davies, E.T., Mieli-Vergani, G., et al. Primary and secondary liver/kidney microsomal autoantibody response following infection with hepatitis C virus. Gastroenterology 106 (1994), 1672–1675.
44. [44] Bjornsson, E., Talwalkar, J., Treeprasertsuk, S., Kamath, P.S., Takahashi, N., Sanderson, S., Neuhauser, M., et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 51 (2010), 2040–2048.
45. [45] Bei, R., Budillon, A., Reale, M.G., Capuano, G., Pomponi, D., Budillon, G., Frati, L., et al. Cryptic epitopes on alpha-fetoprotein induce spontaneous immune responses in hepatocellular carcinoma, liver cirrhosis, and chronic hepatitis patients. Cancer Res. 59 (1999), 5471–5474.
46. [46] Jensen, D.M., McFarlane, I.G., Portmann, B.S., Eddleston, A.L., Williams, R., Detection of antibodies directed against a liver-specific membrane lipoprotein in patients with acute and chronic active hepatitis. N. Engl. J. Med. 299 (1978), 1–7.
47. [47] McFarlane, B.M., McSorley, C.G., Vergani, D., McFarlane, I.G., Williams, R., Serum autoantibodies reacting with the hepatic asialoglycoprotein receptor protein (hepatic lectin) in acute and chronic liver disorders. J. Hepatol. 3 (1986), 196–205.
48. [48] Vergani, G.M., Vergani, D., Jenkins, P.J., Portmann, B., Mowat, A.P., Eddleston, A.L., Williams, R., Lymphocyte cytotoxicity to autologous hepatocytes in HBsAg-negative chronic active hepatitis. Clin. Exp. Immunol. 38 (1979), 16–21.
49. [49] Vergani, D., Mieli-Vergani, G., Mondelli, M., Portmann, B., Eddleston, A.L., Immunoglobulin on the surface of isolated hepatocytes is associated with antibody-dependent cell-mediated cytotoxicity and liver damage. Liver 7 (1987), 307–315.
50. [50] Wies, I., Brunner, S., Henninger, J., Herkel, J., Kanzler, S., Meyer zum Buschenfelde, K.H., Lohse, A.W., Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 355 (2000), 1510–1515.
51. [51] Ma, Y., Okamoto, M., Thomas, M.G., Bogdanos, D.P., Lopes, A.R., Portmann, B., Underhill, J., et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 35 (2002), 658–664.
52. [52] Muratori, L., Parola, M., Ripalti, A., Robino, G., Muratori, P., Bellomo, G., Carini, R., et al. Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane. Gut 46 (2000), 553–561.
53. [53] Harada, K., Shimoda, S., Sato, Y., Isse, K., Ikeda, H., Nakanuma, Y., Periductal interleukin-17 production in association with biliary innate immunity contributes to the pathogenesis of cholangiopathy in primary biliary cirrhosis. Clin. Exp. Immunol. 157 (2009), 261–270.
54. [54] Liberal, R., Grant, C.R., Mieli-Vergani, G., Vergani, D., Longhi, M.S., PWE-281 Different effector T cell responses may account for different patterns of liver injury in childhood autoimmune liver disease. Gut, 61(Suppl. 2), 2012, A412.
55. [55] Zhao, L., Tang, Y., You, Z., Wang, Q., Liang, S., Han, X., Qiu, D., et al. Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression. PLoS One, 6, 2011, e18909.
56. [56] Grant, C.R., Liberal, R., Mieli-Vergani, G., Vergani, D., Longhi, M.S., Regulatory T-cells in autoimmune diseases: challenges, controversies and–yet–unanswered questions. Autoimmun. Rev. 14 (2015), 105–116.
57. [57] Longhi, M.S., Ma, Y., Bogdanos, D.P., Cheeseman, P., Mieli-Vergani, G., Vergani, D., Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J. Hepatol. 41 (2004), 31–37.
58. [58] Longhi, M.S., Mitry, R.R., Samyn, M., Scalori, A., Hussain, M.J., Quaglia, A., Mieli-Vergani, G., et al. Vigorous activation of monocytes in juvenile autoimmune liver disease escapes the control of regulatory T-cells. Hepatology 50 (2009), 130–142.
59. [59] Peiseler, M., Sebode, M., Franke, B., Wortmann, F., Schwinge, D., Quaas, A., Baron, U., et al. FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency. J. Hepatol. 57 (2012), 125–132.
60. [60] Taubert, R., Hardtke-Wolenski, M., Noyan, F., Wilms, A., Baumann, A.K., Schlue, J., Olek, S., et al. Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies. J. Hepatol. 61 (2014), 1106–1114.
61. [61] Liberal, R., Grant, C.R., Holder, B.S., Cardone, J., Martinez-Llordella, M., Ma, Y., Heneghan, M.A., et al. In autoimmune hepatitis type 1 or the autoimmune hepatitis-sclerosing cholangitis variant defective regulatory T-cell responsiveness to IL-2 results in low IL-10 production and impaired suppression. Hepatology 62 (2015), 863–875.
62. [62] Grant, C.R., Liberal, R., Holder, B.S., Cardone, J., Ma, Y., Robson, S.C., Mieli-Vergani, G., et al. Dysfunctional CD39(POS) regulatory T cells and aberrant control of T-helper type 17 cells in autoimmune hepatitis. Hepatology 59 (2014), 1007–1015.
63. [63] Liberal, R., Grant, C.R., Ma, Y., Csizmadia, E., Jiang, Z.G., Heneghan, M.A., Yee, E.U., et al. CD39 mediated regulation of Th17-cell effector function is impaired in juvenile autoimmune liver disease. J. Autoimmun. 66 (2016), 25–39.
64. [64] Hardtke-Wolenski, M., Jaeckel, E., Mouse models for experimental autoimmune hepatitis: limits and chances. Dig. Dis. 28 (2010), 70–79.
65. [65] Lohse, A.W., Manns, M., Dienes, H.P., Meyer zum Buschenfelde KH, Cohen IR. Experimental autoimmune hepatitis: disease induction, time course and T-cell reactivity. Hepatology 11 (1990), 24–30.
66. [66] Derkow, K., Loddenkemper, C., Mintern, J., Kruse, N., Klugewitz, K., Berg, T., Wiedenmann, B., et al. Differential priming of CD8 and CD4 T-cells in animal models of autoimmune hepatitis and cholangitis. Hepatology 46 (2007), 1155–1165.
67. [67] Holdener, M., Hintermann, E., Bayer, M., Rhode, A., Rodrigo, E., Hintereder, G., Johnson, E.F., et al. Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J. Exp. Med. 205 (2008), 1409–1422.
68. [68] Hintermann, E., Ehser, J., Christen, U., The CYP2D6 animal model: how to induce autoimmune hepatitis in mice. J. Vis. Exp.(60), 2012 pii: 3644.
69. [69] Yuksel, M., Wang, Y., Tai, N., Peng, J., Guo, J., Beland, K., Lapierre, P., et al. A novel “humanized mouse” model for autoimmune hepatitis and the association of gut microbiota with liver inflammation. Hepatology 62 (2015), 1536–1550.
70. [70] Lapierre, P., Djilali-Saiah, I., Vitozzi, S., Alvarez, F., A murine model of type 2 autoimmune hepatitis: xenoimmunization with human antigens. Hepatology 39 (2004), 1066–1074.
71. [71] Lapierre, P., Beland, K., Yang, R., Alvarez, F., Adoptive transfer of ex vivo expanded regulatory T cells in an autoimmune hepatitis murine model restores peripheral tolerance. Hepatology 57 (2013), 217–227.
72. [72] Kido, M., Watanabe, N., Okazaki, T., Akamatsu, T., Tanaka, J., Saga, K., Nishio, A., et al. Fatal autoimmune hepatitis induced by concurrent loss of naturally arising regulatory T cells and PD-1-mediated signaling. Gastroenterology 135 (2008), 1333–1343.
73. [73] Muller, P., Messmer, M., Bayer, M., Pfeilschifter, J.M., Hintermann, E., Christen, U., Non-alcoholic fatty liver disease (NAFLD) potentiates autoimmune hepatitis in the CYP2D6 mouse model. J. Autoimmun. 69 (2016), 51–58.
74. [74] Stravitz, R.T., Lefkowitch, J.H., Fontana, R.J., Gershwin, M.E., Leung, P.S., Sterling, R.K., Manns, M.P., et al. Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology 53 (2011), 517–526.
75. [75] Feld, J.J., Dinh, H., Arenovich, T., Marcus, V.A., Wanless, I.R., Heathcote, E.J., Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 42 (2005), 53–62.
76. [76] Floreani, A., Liberal, R., Vergani, D., Mieli-Vergani, G., Autoimmune hepatitis: contrasts and comparisons in children and adults – a comprehensive review. J. Autoimmun. 46 (2013), 7–16.
77. [77] Krawitt, E.L., Autoimmune hepatitis. N. Engl. J. Med. 354 (2006), 54–66.
78. [78] Gregorio, G.V., Portmann, B., Reid, F., Donaldson, P.T., Doherty, D.G., McCartney, M., Mowat, A.P., et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 25 (1997), 541–547.
79. [79] Yeoman, A.D., Al-Chalabi, T., Karani, J.B., Quaglia, A., Devlin, J., Mieli-Vergani, G., Bomford, A., et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: implications for follow-up and screening. Hepatology 48 (2008), 863–870.
80. [80] Vierling, J.M., Autoimmune hepatitis and overlap syndromes: diagnosis and management. Clin. Gastroenterol. Hepatol. 13 (2015), 2088–2108.
81. [81] Vergani, D., Alvarez, F., Bianchi, F.B., Cancado, E.L., Mackay, I.R., Manns, M.P., Nishioka, M., et al. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the international autoimmune hepatitis group. J. Hepatol. 41 (2004), 677–683.
82. [82] Liberal, R., Grant, C.R., Longhi, M.S., Mieli-Vergani, G., Vergani, D., Diagnostic criteria of autoimmune hepatitis. Autoimmun. Rev. 13 (2014), 435–440.
83. [83] Meroni, P.L., Schur, P.H., ANA screening: an old test with new recommendations. Ann. Rheum. Dis. 69 (2010), 1420–1422.
84. [84] Manns, M., Gerken, G., Kyriatsoulis, A., Staritz, M., Meyer zum Buschenfelde KH. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1 (1987), 292–294.
85. [85] Strassburg, C.P., Obermayer-Straub, P., Alex, B., Durazzo, M., Rizzetto, M., Tukey, R.H., Manns, M.P., Autoantibodies against glucuronosyltransferases differ between viral hepatitis and autoimmune hepatitis. Gastroenterology 111 (1996), 1576–1586.
86. [86] Philipp, T., Durazzo, M., Trautwein, C., Alex, B., Straub, P., Lamb, J.G., Johnson, E.F., et al. Recognition of uridine diphosphate glucuronosyl transferases by LKM-3 antibodies in chronic hepatitis D. Lancet 344 (1994), 578–581.
87. [87] Czaja, A.J., Carpenter, H.A., Autoimmune hepatitis. Macsween, R.N.M., Burt, A.D., Portmann, B.C., (eds.) Pathology of the Liver, fourth ed., 2001, Churchill Livingstone, 415–434.
88. [88] Miao, Q., Bian, Z., Tang, R., Zhang, H., Wang, Q., Huang, S., Xiao, X., et al. Emperipolesis mediated by CD8 T cells is a characteristic histopathologic feature of autoimmune hepatitis. Clin. Rev. Allergy Immunol. 48 (2015), 226–235.
89. [89] de Boer, Y.S., van Nieuwkerk, C.M., Witte, B.I., Mulder, C.J., Bouma, G., Bloemena, E., Assessment of the histopathological key features in autoimmune hepatitis. Histopathology 66 (2015), 351–362.
90. [90] Maggiore, G., Bernard, O., Homberg, J.C., Hadchouel, M., Alvarez, F., Hadchouel, P., Odievre, M., et al. Liver disease associated with anti-liver-kidney microsome antibody in children. J. Pediatr. 108 (1986), 399–404.
91. [91] Tiniakos, D.G., Brain, J.G., Bury, Y.A., Role of histopathology in autoimmune hepatitis. Dig. Dis. 33:Suppl. 2 (2015), 53–64.
92. [92] Di Giorgio, A., Bravi, M., Bonanomi, E., Alessio, G., Sonzogni, A., Zen, Y., Colledan, M., et al. Fulminant hepatic failure of autoimmune aetiology in children. J. Pediatr. Gastroenterol. Nutr. 60 (2015), 159–164.
93. [93] European Association for the Study of the L, EASL clinical practice guidelines: autoimmune hepatitis. J. Hepatol. 63 (2015), 971–1004.
94. [94] Czaja, A.J., Freese, D.K., American association for the study of liver D. Diagnosis and treatment of autoimmune hepatitis. Hepatology 36 (2002), 479–497.
95. [95] Muratori, L., Muratori, P., Lanzoni, G., Ferri, S., Lenzi, M., Application of the 2010 American Association for the study of liver diseases criteria of remission to a cohort of Italian patients with autoimmune hepatitis. Hepatology 52 (2010), 1857–1858 author reply.
96. [96] Manns, M.P., Woynarowski, M., Kreisel, W., Lurie, Y., Rust, C., Zuckerman, E., Bahr, M.J., et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 139 (2010), 1198–1206.
97. [97] Woynarowski, M., Nemeth, A., Baruch, Y., Koletzko, S., Melter, M., Rodeck, B., Strassburg, C.P., et al. Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents. J. Pediatr. 163 (2013), 1347–1353.
98. [98] Mieli-Vergani, G., Vergani, D., Budesonide for juvenile autoimmune hepatitis? Not yet. J. Pediatr. 163 (2013), 1246–1248.
99. [99] Mieli-Vergani, G., Heller, S., Jara, P., Vergani, D., Chang, M.H., Fujisawa, T., Gonzalez-Peralta, R.P., et al. Autoimmune hepatitis. J. Pediatr. Gastroenterol. Nutr. 49 (2009), 158–164.
100. [100] Hempfling, W., Grunhage, F., Dilger, K., Reichel, C., Beuers, U., Sauerbruch, T., Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology 38 (2003), 196–202.
101. [101] Lamers, M.M., van Oijen, M.G., Pronk, M., Drenth, J.P., Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials. J. Hepatol. 53 (2010), 191–198.
102. [102] van Gerven, N.M., Verwer, B.J., Witte, B.I., van Hoek, B., Coenraad, M.J., van Erpecum, K.J., Beuers, U., et al. Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J. Hepatol. 58 (2013), 141–147.
103. [103] Vergani, D., Mieli-Vergani, G., Pharmacological management of autoimmune hepatitis. Expert Opin. Pharmacother. 12 (2011), 607–613.
104. [104] Hennes, E.M., Oo, Y.H., Schramm, C., Denzer, U., Buggisch, P., Wiegard, C., Kanzler, S., et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis?. Am. J. Gastroenterol. 103 (2008), 3063–3070.
105. [105] Sharzehi, K., Huang, M.A., Schreibman, I.R., Brown, K.A., Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy. Can. J. Gastroenterol. 24 (2010), 588–592.
106. [106] Pratt, D.S., Flavin, D.P., Kaplan, M.M., The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine. Gastroenterology 110 (1996), 271–274.
107. [107] Hubener, S., Oo, Y.H., Than, N.N., Hubener, P., Weiler-Normann, C., Lohse, A.W., Schramm, C., Efficacy of 6-mercaptopurine as second-line treatment for patients with autoimmune hepatitis and azathioprine intolerance. Clin. Gastroenterol. Hepatol. 14 (2016), 445–453.
108. [108] Gordon, M., Taylor, K., Akobeng, A.K., Thomas, A.G., Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease. Cochrane Database Syst. Rev., 8, 2014, CD010233.
109. [109] Sebode, M., Schramm, C., AIH: which alternative for difficult-to-treat patients?. Dig. Dis. 33:Suppl. 2 (2015), 83–87.
110. [110] Hlivko, J.T., Shiffman, M.L., Stravitz, R.T., Luketic, V.A., Sanyal, A.J., Fuchs, M., Sterling, R.K., A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. Clin. Gastroenterol. Hepatol. 6 (2008), 1036–1040.
111. [111] Aw, M.M., Dhawan, A., Samyn, M., Bargiota, A., Mieli-Vergani, G., Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. J. Hepatol. 51 (2009), 156–160.
112. [112] Larsen, F.S., Vainer, B., Eefsen, M., Bjerring, P.N., Adel Hansen, B., Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J. Gastroenterol. 13 (2007), 3232–3236.
113. [113] Than, N.N., Wiegard, C., Weiler-Normann, C., Fussel, K., Mann, J., Hodson, J., Hirschfield, G.M., et al. Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on Tacrolimus therapy. Scand. J. Gastroenterol. 51 (2016), 329–336.
114. [114] Weiler-Normann, C., Schramm, C., Quaas, A., Wiegard, C., Glaubke, C., Pannicke, N., Moller, S., et al. Infliximab as a rescue-treatment in difficult-to-treat autoimmune hepatitis. J. Hepatol. 58 (2013), 529–534.
115. [115] Barth, E., Clawson, J., A case of autoimmune hepatitis treated with rituximab. Case Rep. Gastroenterol. 4 (2010), 502–509.
116. [116] Chatrath, H., Allen, L., Boyer, T.D., Use of sirolimus in the treatment of refractory autoimmune hepatitis. Am. J. Med. 127 (2014), 1128–1131.
117. [117] Ytting, H., Larsen, F.S., Everolimus treatment for patients with autoimmune hepatitis and poor response to standard therapy and drug alternatives in use. Scand. J. Gastroenterol. 50 (2015), 1025–1031.
118. [118] Liberal, R., Zen, Y., Mieli-Vergani, G., Vergani, D., Liver transplantation and autoimmune liver diseases. Liver Transpl. 19 (2013), 1065–1077.
119. [119] Futagawa, Y., Terasaki, P.I., An analysis of the OPTN/UNOS liver transplant registry. Clin. Transpl., 2004, 315–329.
120. [120] Kerkar, N., Yanni, G., ‘De novo’ and ‘recurrent’ autoimmune hepatitis after liver transplantation: a comprehensive review. J. Autoimmun. 66 (2016), 17–24.
121. [121] Campsen, J., Zimmerman, M.A., Trotter, J.F., Wachs, M., Bak, T., Steinberg, T., Kaplan, M., et al. Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal. Liver Transpl. 14 (2008), 1281–1286.
122. [122] Montano-Loza, A.J., Mason, A.L., Ma, M., Bastiampillai, R.J., Bain, V.G., Tandon, P., Risk factors for recurrence of autoimmune hepatitis after liver transplantation. Liver Transpl. 15 (2009), 1254–1261.
123. [123] Kerkar, N., Hadzic, N., Davies, E.T., Portmann, B., Donaldson, P.T., Rela, M., Heaton, N.D., et al. De-novo autoimmune hepatitis after liver transplantation. Lancet 351 (1998), 409–413.
124. [124] Salcedo, M., Vaquero, J., Banares, R., Rodriguez-Mahou, M., Alvarez, E., Vicario, J.L., Hernandez-Albujar, A., et al. Response to steroids in de novo autoimmune hepatitis after liver transplantation. Hepatology 35 (2002), 349–356.
125. [125] Boberg, K.M., Chapman, R.W., Hirschfield, G.M., Lohse, A.W., Manns, M.P., Schrumpf, E., International Autoimmune hepatitis G. Overlap syndromes: the international autoimmune hepatitis group (IAIHG) position statement on a controversial issue. J. Hepatol. 54 (2011), 374–385.
126. [126] Chazouilleres, O., Wendum, D., Serfaty, L., Montembault, S., Rosmorduc, O., Poupon, R., Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 28 (1998), 296–301.
127. [127] Czaja, A.J., Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 28 (1998), 360–365.
128. [128] European Association for the Study of the L, EASL clinical practice guidelines: management of cholestatic liver diseases. J. Hepatol. 51 (2009), 237–267.
129. [129] Chazouilleres, O., Wendum, D., Serfaty, L., Rosmorduc, O., Poupon, R., Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. J. Hepatol. 44 (2006), 400–406.
130. [130] Floreani, A., Rizzotto, E.R., Ferrara, F., Carderi, I., Caroli, D., Blasone, L., Baldo, V., Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am. J. Gastroenterol. 100 (2005), 1516–1522.
131. [131] Gregorio, G.V., Portmann, B., Karani, J., Harrison, P., Donaldson, P.T., Vergani, D., Mieli-Vergani, G., Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 33 (2001), 544–553.
132. [132] Abdalian, R., Dhar, P., Jhaveri, K., Haider, M., Guindi, M., Heathcote, E.J., Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging. Hepatology 47 (2008), 949–957.
133. [133] Kessler, W.R., Cummings, O.W., Eckert, G., Chalasani, N., Lumeng, L., Kwo, P.Y., Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin. Gastroenterol. Hepatol. 2 (2004), 625–631.
134. [134] Ichai, P., Duclos-Vallee, J.C., Guettier, C., Hamida, S.B., Antonini, T., Delvart, V., Saliba, F., et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl. 13 (2007), 996–1003.
135. [135] Potts, J.R., Verma, S., Optimizing management in autoimmune hepatitis with liver failure at initial presentation. World J. Gastroenterol. 17 (2011), 2070–2075.
136. [136] Verma, S., Gunuwan, B., Mendler, M., Govindrajan, S., Redeker, A., Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am. J. Gastroenterol. 99 (2004), 1510–1516.
137. [137] Yeoman, A.D., Westbrook, R.H., Zen, Y., Bernal, W., Al-Chalabi, T., Wendon, J.A., O'Grady, J.G., et al. Prognosis of acute severe autoimmune hepatitis (AS-AIH): the role of corticosteroids in modifying outcome. J. Hepatol. 61 (2014), 876–882.
138. [138] Miyake, Y., Iwasaki, Y., Terada, R., Onishi, T., Okamoto, R., Sakai, N., Sakaguchi, K., et al. Clinical characteristics of fulminant-type autoimmune hepatitis: an analysis of eleven cases. Aliment. Pharmacol. Ther. 23 (2006), 1347–1353.
139. [139] Chen, M., Suzuki, A., Borlak, J., Andrade, R.J., Lucena, M.I., Drug-induced liver injury: interactions between drug properties and host factors. J. Hepatol. 63 (2015), 503–514.
140. [140] Wang, Q., Yang, F., Miao, Q., Krawitt, E.L., Gershwin, M.E., Ma, X., The clinical phenotypes of autoimmune hepatitis: a comprehensive review. J. Autoimmun. 66 (2016), 98–107.
141. [141] Suzuki, A., Brunt, E.M., Kleiner, D.E., Miquel, R., Smyrk, T.C., Andrade, R.J., Lucena, M.I., et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology 54 (2011), 931–939.
142. [142] Schramm, C., Herkel, J., Beuers, U., Kanzler, S., Galle, P.R., Lohse, A.W., Pregnancy in autoimmune hepatitis: outcome and risk factors. Am. J. Gastroenterol. 101 (2006), 556–560.
143. [143] Westbrook, R.H., Yeoman, A.D., Kriese, S., Heneghan, M.A., Outcomes of pregnancy in women with autoimmune hepatitis. J. Autoimmun. 38 (2012), J239–J244.
144. [144] Lohse, A.W., Mieli-Vergani, G., Autoimmune hepatitis. J. Hepatol. 55 (2011), 171–182.